Investing.com - Financial Markets Worldwide

Isu Abxis Co Ltd (086890)

KOSDAQ
Currency in KRW
5,330
+80(+1.52%)
Closed·
086890 Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
Unusual trading volume
Earnings results expected in 0 days
086890 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
5,2305,650
52 wk Range
3,9457,070
Key Statistics
Edit
Bid/Ask
5,330.00 / 5,340.00
Prev. Close
5,250
Open
5,250
Day's Range
5,230-5,650
52 wk Range
3,945-7,070
Volume
690.58K
Average Volume (3m)
159.39K
1-Year Change
-15.94%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
086890 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Neutral
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 8
Trading at a low earnings multiple
Unlock InvestingPro

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Sell

Isu Abxis Co Ltd Company Profile

ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; Clotinab, an abciximab that is used as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications; Febulein, a sodium phenylbutyrate granule for the treatment of urea dystrophy; and Trientop, a trientine hydrochloride capsule for the treatment of Wilson’s disease. It develops ISU104 for head, neck, colorectal, and breast cancer; ISU104 CAR-NK for leukemia and solid tumors; ABX2001 for solid tumors; ISU304 for hemophilia B; ISU305 for paroxysmal nocturnal hemoglobinuria and other autoimmune diseases; and ISU203 for dementia caused by Alzheimer’s disease. The company was formerly known as Petagen Co., Ltd. and changed its name to ISU Abxis Co., Ltd. in November 2004. ISU Abxis Co., Ltd. was founded in 2001 and is headquartered in Seongnam-si, South Korea.

Industry
Pharmaceuticals
Sector
Healthcare
Employees
178
Market
South Korea

Compare 086890 to Peers and Sector

Metrics to compare
086890
Peers
Sector
Relationship
P/E Ratio
9.3x−8.4x−0.5x
PEG Ratio
0.03−0.130.00
Price/Book
2.1x2.7x2.6x
Price / LTM Sales
4.1x5.5x3.3x
Upside (Analyst Target)
-0.0%43.4%
Fair Value Upside
Unlock25.0%7.1%Unlock

Earnings

Latest Release
May 19, 2025
EPS / Forecast
-244.01 / --
Revenue / Forecast
7.18B / --
EPS Revisions
a
a
Unlock
Last 90 days

086890 Income Statement

FAQ

What Stock Exchange Does Isu Abxis Trade On?

Isu Abxis is listed and trades on the KOSDAQ stock exchange.

What Is the Stock Symbol for Isu Abxis?

The stock symbol for Isu Abxis is "086890."

What Is the Isu Abxis Market Cap?

As of today, Isu Abxis market cap is 210.53B.

What Is Isu Abxis's Earnings Per Share (TTM)?

The Isu Abxis EPS (TTM) is 624.45.

When Is the Next Isu Abxis Earnings Date?

Isu Abxis will release its next earnings report on 12 Aug 2025.

From a Technical Analysis Perspective, Is 086890 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Isu Abxis Stock Split?

Isu Abxis has split 2 times.

How Many Employees Does Isu Abxis Have?

Isu Abxis has 178 employees.

What is the current trading status of Isu Abxis (086890)?

As of 08 Aug 2025, Isu Abxis (086890) is trading at a price of 5,330.00, with a previous close of 5,250.00. The stock has fluctuated within a day range of 5,230.00 to 5,650.00, while its 52-week range spans from 3,945.00 to 7,070.00.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.